Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Karen A AutioChristopher A KlebanoffDavid SchaerJohn Sae Wook KauhSusan F SlovinMatthew J AdamowVictoria S BlinderManisha BrahmacharyMichelle CarlsenElizabeth ComenDaniel C DanilaThompson N DomanJeremy C DurackJosef J FoxJill S GluskinDavid M HoffmanSuhyun KangPraneet KangJonathan LandaPhilomena F McAndrewShanu ModiMichael J MorrisRuslan NovosiadlyDana E RathkopfRachel SanfordSonya C ChapmanCourtney M TateDanni YuPhillip WongHeather L McArthurPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
LY3022855 was well tolerated and showed evidence of immune modulation. Clinically meaningful stable disease >9 months was observed in two patients with MBC.
Keyphrases